Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD34+ Stem Cell Selection for GVHD Prevention in Pediatric Malignancies
NCT02061800Phase 2Active, not recruiting
- Start
- Jun 2013
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 2, open-label trial (3 arms). Primary endpoint: Incidence of acute GVHD at 2 years. Started Jun 2013; status: active, not recruiting.
Beyond the preview
Go deeper on NCT02061800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02061800.